{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:10:38Z","timestamp":1788876638813,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Urothelial carcinoma (UC) remains a persistent clinical challenge in the post-Bacillus Calmette-Gu\u00e9rin (BCG) era, particularly because a substantial proportion of patients with high-risk non-muscle-invasive bladder cancer (NMIBC) experience recurrence or progression despite standard intravesical immunotherapy. Although immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have expanded the therapeutic armamentarium, widely studied biomarkers such as tumor mutational burden (TMB) and PD-L1 expression show limited and inconsistent predictive performance in UC, which may partly reflect their inability to capture the spatial organization and functional states of the tumor immune microenvironment (TIME). Tertiary lymphoid structures (TLS), ectopic lymphoid aggregates that develop in non-lymphoid tissues at sites of chronic inflammation or cancer, have emerged as candidate mediators and spatial markers of local adaptive immunity. In UC, TLS appear to exhibit spatial heterogeneity and may exist across a maturation continuum from early, disorganized lymphoid aggregates to mature, germinal center-containing follicles; their localization within the lamina propria, tumor stroma, or invasive front may be associated with distinct immune contexts and clinical outcomes. This review provides a urology-centric perspective on TLS biology in UC, emphasizing how the anatomical and immunological niche of the bladder, including urinary exposure, the urinary microbiome, BCG-associated inflammation, and stromal remodeling, may shape the conditions under which TLS develop and function. We critically discuss TLS maturation status as a potential spatial biomarker, while emphasizing that its relationship with BCG failure and subsequent response to PD-1\/PD-L1 blockade or enfortumab vedotin (EV)-based therapy remains largely correlative and requires prospective validation. Furthermore, we explore emerging strategies that may modulate TLS-associated immune architecture, including STING agonist instillation and LT\u03b2R pathway modulation, and discuss how TLS could be tested as an adjunctive biomarker in future bladder-preservation studies for high-risk T1 disease. By synthesizing current evidence and methodological advances in spatial transcriptomics, we underscore the translational imperative of viewing UC as a malignancy with heterogeneous local immune architecture, including candidate tertiary lymphoid structures. At present, TLS should not be used as a stand-alone biomarker for selecting bladder preservation, radical cystectomy, intravesical therapy continuation, or systemic treatment switching.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1853633","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:47:47Z","timestamp":1788875267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tertiary lymphoid structures in urothelial carcinoma: bridging spatial architecture with therapeutic vulnerability in the post-BCG era"],"prefix":"10.3389","volume":"17","author":[{"given":"Xin","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Urology, China-Japan Union Hospital, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Urology, China-Japan Union Hospital, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, China-Japan Union Hospital, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-017-0271-0","article-title":"Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of bladder carcinoma","volume":"5","author":"Kamat","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02572-9","article-title":"Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1\/PD-L1 blockade in muscle-invasive bladder cancer","volume":"130","author":"Su","year":"2024","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-170120","article-title":"Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer","volume":"3","author":"Koti","year":"2017","journal-title":"Bladder Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410998","article-title":"Tertiary lymphoid structures are linked to enhanced antitumor immunity and better prognosis in muscle-invasive bladder cancer","volume":"12","author":"Lin","year":"2025","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.793964","article-title":"The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer","volume":"12","author":"van Dijk","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad283","article-title":"Presence, subtypes, and prognostic significance of tertiary lymphoid structures in urothelial carcinoma of the bladder","volume":"29","author":"Ma","year":"2024","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-025-01314-z","article-title":"The emerging role of B cells and tertiary lymphoid structures in bladder cancer","volume":"27","author":"Penunuri","year":"2025","journal-title":"Curr Urol Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001939","article-title":"The roles of tertiary lymphoid structures in genitourinary cancers: molecular mechanisms, therapeutic strategies, and clinical applications","volume":"110","author":"Yang","year":"2024","journal-title":"Int J Surg (London England)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1787200","article-title":"Tertiary lymphoid structures in genitourinary cancers: a comprehensive review","volume":"16","author":"Abreu","year":"2026","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031732","article-title":"The urinary microbiome in health and disease: Relevance for bladder cancer","volume":"25","author":"Kustrimovic","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.10.002","article-title":"The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer","volume":"8","author":"Huang","year":"2020","journal-title":"Genes Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/35018581","article-title":"A chemokine-driven positive feedback loop organizes lymphoid follicles","volume":"406","author":"Ansel","year":"2000","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.53986\/ibjm.2020.0062","article-title":"A review on the evolution of immunotherapy in bladder carcinoma","volume":"2","author":"Gulinac","year":"2020","journal-title":"Iberoamerican J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2021.0029","article-title":"Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies","volume":"18","author":"Zhao","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369626","article-title":"Tertiary lymphoid structures in cancer: maturation and induction","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1413067","article-title":"Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy","volume":"15","author":"Bao","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101406","article-title":"Tertiary lymphoid structures and B cells: Clinical impact and therapeutic modulation in cancer","volume":"48","author":"Sautes-Fridman","year":"2020","journal-title":"Semin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67428","article-title":"CD4+ follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Gu-Trantien","year":"2013","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003883","article-title":"Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer","volume":"10","author":"Masuda","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0431","article-title":"Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer","volume":"71","author":"Martinet","year":"2011","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-21-0123","article-title":"Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells","volume":"2","author":"Milutinovic","year":"2022","journal-title":"Cancer Res Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.07.002","article-title":"High endothelial venules as potential gateways for therapeutics","volume":"43","author":"Hussain","year":"2022","journal-title":"Trends Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094776","article-title":"Spatial distribution of macrophage and lymphocyte subtypes within tumor microenvironment to predict recurrence of non-muscle-invasive papillary urothelial carcinoma after BCG immunotherapy","volume":"25","author":"Drachneris","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020294","article-title":"Potential role of CXCL13\/CXCR5 signaling in immune checkpoint inhibitor treatment in cancer","volume":"14","author":"Hsieh","year":"2022","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0201","article-title":"Escherichia coli-specific CXCL13-producing T follicular helper cells are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer","volume":"12","author":"Peguillet","year":"2022","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Kamat","year":"2021","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Park","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Valderrama","year":"2024","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/CU9.0000000000000204","article-title":"Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review","volume":"17","author":"Bantounou","year":"2023","journal-title":"Curr Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2482363","article-title":"Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer","volume":"21","author":"Sternschuss","year":"2025","journal-title":"Future Oncol (London England)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-5581","article-title":"Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers","volume":"80","author":"Liu","year":"2020","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173071","article-title":"Mechanistic insights into the successful development of combination therapy of enfortumab vedotin and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer","volume":"16","author":"Taylor","year":"2024","journal-title":"Cancers"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-1022","article-title":"STING agonist VB-85247 induces durable antitumor immune responses by intravesical administration in a non-muscle-invasive bladder cancer","volume":"85","author":"Prabagar","year":"2025","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-3269","article-title":"Abstract 3269: Discovery and characterization of E7766, a novel macrocycle-bridged STING agonist with pan-genotypic and potent antitumor activity through intravesical and intratumoral administration","volume":"79","author":"Huang","year":"2019","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0758","article-title":"The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes","volume":"7","author":"Pfannstiel","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aaf2403","article-title":"Visualization and analysis of gene expression in tissue sections by spatial transcriptomics","volume":"353","author":"St\u00e5hl","year":"2016","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.1001-1420.2021.05.018","article-title":"Progress in clinical treatment of upper tract urothelial carcinoma","volume":"39","author":"Chen","year":"2024","journal-title":"J Clin Urol (China)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1853633\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:47:48Z","timestamp":1788875268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1853633\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1853633"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1853633","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1853633"}}